Company

LiveKidney.BIO

Biotechnology Research A Wide Range of Kidney-related Diseases. 5 employees MYSZ

Employees: 5
Contacts: 1
Emails: 1

livekidney.bio LinkedIn

LiveKidney.BIO Overview

Headquarters: A Wide Range of Kidney-related Diseases.
Website: livekidney.bio
Industry: Biotechnology Research
Employees: 5
Stock Symbol: MYSZ
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Tel aviv

About LiveKidney.BIO

LiveKidney is a clinical-stage cell therapy company that develops proprietary, pharmaceutical grade, hydrogel-based formulations of umbilical cord Mesenchymal Stromal Cells (UC-MSCs) to treat advanced kidney disease and prevent its progression towards kidney failure. The company' s products allow the continuous release of bioactive compounds from the UC-MSCs to the kidneys via unique routes of administration, triggering anti-inflammatory and anti-fibrotic effects through a systemic and local effect. Our pipeline of future products is based on our proprietary delivery platform and is designed to address a wide range of kidney-related diseases.

LiveKidney.BIO Contact Details

People in AeroLeads: 3
With contact data: 1
Email contacts: 1; 33.3% coverage

LiveKidney.BIO Org Chart

Sample employees and titles

Name	Title	Location	Contact
Walter Wasser	CEO, Bduk Therapeutics - Senior	Tel Aviv-yafo, Tel Aviv District, Israel	View
Shimon Amselem	Chief Scientist, Delivery Technologies		View
Roy Golan	Financial Advisor, Investor and Board	Israel	Email